Concept appoints Matilda Bingham & David Higton

Matilda has over 15 years’ experience in the pharmaceutical industry, in both biotech and pharma environments. She joins Concept from Redx Pharma, where she held positions as Head of Research and Operations, and Executive Director of Oncology and Immunology. Matilda previously also worked for MSD Research Laboratories (part of Merck). With a PhD in Organic Chemistry, Matilda has had numerous publications, patents and posters published, and has managed programmes from hit-to-lead through to the clinic across a diverse range of target classes and disease areas.
 
David is a highly experienced scientist with a proven track record of delivering innovative, effective solutions. He has over 34 years of expertise in bioanalytical and biotransformation studies, including 23 years at Glaxo Group Research, now GlaxoSmithKline, where he supported pre-clinical, clinical, and discovery investigations, for both non-GLP and GLP studies. David joins Concept from Cyprotex, where he was most recently Head of Analytical Sciences. Prior to this he was Analytical Team Leader at RedX Pharma, Vice President, Operations at Xceleron Inc, and Principal Scientist at AstraZeneca, leading new scientific and technological development in regulatory bioanalysis.